分析中国人晚期非小细胞肺癌棘皮动物微管相关蛋白样-4-间变性淋巴瘤激酶融合基因的临床病理特征。

Analysis of clinicopathological features of the echinoderm microtubule-associated protein-like-4-anaplastic lymphoma kinase fusion gene in Chinese patients with advanced non-small-cell lung cancer.

机构信息

Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs Beijing, China.

出版信息

Thorac Cancer. 2014 May;5(3):255-60. doi: 10.1111/1759-7714.12101. Epub 2014 Apr 22.

DOI:10.1111/1759-7714.12101

PMID:26767009

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4704311/

Abstract

BACKGROUND

The echinoderm microtubule-associated protein-like-4-anaplastic lymphoma kinase (EML4-ALK) fusion gene defines a novel molecular subset of non-small-cell lung cancer (NSCLC). However, the clinicopathological features of patients with the EML4-ALK fusion gene have not been defined completely.

METHODS

Clinicopathological data of 200 Chinese patients with advanced NSCLC were analyzed retrospectively to explore their possible correlations with EML4-ALK fusions.

RESULTS

The EML4-ALK fusion gene was detected in 56 (28.0%) of the 200 NSCLC patients, and undetected in 22 (11.0%) patients because of an insufficient amount of pathological tissue. The median age of the patients with positive and negative EML4-ALK was 48 and 55 years, respectively. Patients with the EML4-ALK fusion gene were significantly younger (P< 0.001). The detection rate of the EML4-ALK fusion gene in patients who received primary tumor or metastatic lymph node resection was significantly higher than in patients who received fine-needle biopsy (P= 0.003). The detection rate of the EML4-ALK fusion gene in patients with a time lag from obtainment of the pathological tissue to EML4-ALK fusion gene detection ≤48 months was significantly higher than in patients >48 months (P= 0.020). The occurrence of the EML4-ALK fusion gene in patients with wild-type epidermal growth factor receptor (EGFR) was significantly higher than in patients with mutant-type EGFR (42.5% [37/87] vs. 6.3% [1/16], P= 0.005).

CONCLUSIONS

Younger age and wild-type EGFR were identified as clinicopathological characteristics of patients with advanced NSCLC who harbored the EML4-ALK fusion gene. The optimal time lag from the obtainment of the pathological tissue to the time of EML4-ALK fusion gene detection is ≤48 months.

摘要

背景

棘皮动物微管相关蛋白样-4-间变性淋巴瘤激酶（EML4-ALK）融合基因定义了非小细胞肺癌（NSCLC）的一个新的分子亚型。然而，EML4-ALK 融合基因患者的临床病理特征尚未完全定义。

方法

回顾性分析 200 例晚期 NSCLC 中国患者的临床病理资料，探讨其与 EML4-ALK 融合的可能相关性。

结果

在 200 例 NSCLC 患者中，检测到 EML4-ALK 融合基因 56 例（28.0%），由于病理组织量不足，22 例（11.0%）患者未检出。阳性和阴性 EML4-ALK 的患者中位年龄分别为 48 岁和 55 岁。携带 EML4-ALK 融合基因的患者明显年轻（P<0.001）。接受原发肿瘤或转移淋巴结切除的患者 EML4-ALK 融合基因的检出率明显高于接受细针活检的患者（P=0.003）。从获得病理组织到 EML4-ALK 融合基因检测的时间间隔≤48 个月的患者中 EML4-ALK 融合基因的检出率明显高于时间间隔>48 个月的患者（P=0.020）。野生型表皮生长因子受体（EGFR）患者中 EML4-ALK 融合基因的发生率明显高于突变型 EGFR 患者（42.5%[37/87] vs. 6.3%[1/16]，P=0.005）。